The Links Between Executive and Linguistic Processes and Their Lesional Determinants From a Verbal Fluency Task

NCT ID: NCT05875103

Last Updated: 2025-05-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

302 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-16

Study Completion Date

2029-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Verbal fluency test require to produce as much words as possible in one or two minutes. This test is highly sensitive to main brain diseases and are therefore widely used in clinical routine for diagnostic purpose. The verbal fluency task requires several cognitive processes including executive and linguistic processes for which it is difficult to extract the origin of the deficit. For this reason, fluency tests are variably interpreted in terms of executive or language. The implementation of an experimental protocol exploring each of these processes separately and studying the links between the verbal fluency task and each of these processes should allow a better understanding of the origin of the verbal fluency deficit after brain injury and improve the identification of key brain structures.

Indeed, the lesion determinants of this task remain to be clarified despite remarkable advances due to the evolution of imaging techniques (voxel-based lesion-symptom mapping (VLSM); voxel-based morphometry (VBM)).

Furthermore, while the direct assessment of linguistic process, semantic memory, and processing speed is well defined, the examination of the executive component (i.e., strategic search process) remains unsettled and will be undertaken in this study.

This work will take advantage of data from previous multicenter work, validated methodologies for both analysis and interpretation of cognitive performance as well as anatomic-clinical correlations at the voxel level and will be performed in cognitive neurodegenerative and cerebrovascular disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Neurodegenerative Stroke Verbal Fluency Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cognitive cortical neurodegenerative diseases and stroke PATIENTS

Group Type EXPERIMENTAL

linguistic processes

Intervention Type DIAGNOSTIC_TEST

Linguistic processes are assessed by performance score on the following tests:

* naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)
* vocabulary test (Mill Hill - Deltour, 1993),
* repetition tests (Gremots - Bézy et al., 2016),
* articulatory speed (Majerus, 2014 ; Roussel et al., 2012)
* semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),
* semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),
* phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

linguistic processes

Linguistic processes are assessed by performance score on the following tests:

* naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011)
* vocabulary test (Mill Hill - Deltour, 1993),
* repetition tests (Gremots - Bézy et al., 2016),
* articulatory speed (Majerus, 2014 ; Roussel et al., 2012)
* semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011),
* semantic categorization and attributes adapted from the BECS-GRECO (Merck et al., 2011),
* phonologic and semantic research tasks adapted from the color TMT (D'helia et al., 1996)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For Cognitive cortical neurodegenerative diseases PATIENTS
* informed consentPatients between 40 and 85 years old,
* French native language,
* Social Security affiliation,
* Can read, write and count (up to 36) and knows the alphabet
* Assessed in Amiens University Memory Clinic for:
* Mild severity impairment (MMSE\> 19) or major severity impairment related to:
* AD according to Albert criteria and McKhann criteria
* DCL according to McKeith criteria
* FTLD according to Rascovsky criteria
* CBD according to Armstrong's criteria
* PSP according to Höglinger criteria
* For Stroke PATIENTS
* informed consent
* Patients between 40 and 85 years old,
* French native language,
* Social Security affiliation,
* Can read, write and count (up to 36) and knows the alphabet
* Having suffered a stroke, hospitalized in neurology, visualized by imaging

Exclusion Criteria

* Mental retardation or guardianship
* Other current or past brain condition affecting cognition, including:
* Severe head trauma
* Epilepsy prior to stroke still requiring previous treatment
* Parkinson disease, multiple sclerosis
* Brain tumor or brain radiation therapy
* Current or past schizophrenia or psychosis
* Active or past psychiatric impairments requiring a stay\> 2 days in a specialized environment
* Contra indication to MRI
* Comorbidity with life expectancy \<1 year
* Comorbidity affecting cognition in particular:
* Alcohol (\> 3 glasses / day) or history of alcohol withdrawal syndrome
* Opiate or cocaine addiction or opiate withdrawal syndrome
* Renal failure (dialysis or creatinine clearance \<30)
* Hepatic failure (spontaneous INR\> 1.5 or PT \<60%)
* Respiratory failure requiring oxygen therapy
* Heart failure (orthopnea\> 2 pillows)
* Persistent vigilance disorder (NIHSS1a score ≤1)
* Cancer with paraneoplastic syndrome
* Treatment with gold salts, D Penicillamine or other treatment with cognitive effect
* Patient under guardianship or curators or private under public law
* Pregnant and / or lactating woman
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire, Amiens

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Amiens

Amiens, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Martine ROUSSEL, PhD

Role: CONTACT

0322668240

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Martine Roussel, PhD

Role: primary

0322667813

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PI2022_843_0150

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.